Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/80686
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Hsp90: still a viable target in prostate cancer
Author: Centenera, M.
Fitzpatrick, A.
Tilley, W.
Butler, L.
Citation: Biochimica et Biophysica Acta-Reviews on Cancer, 2013; 1835(2):211-218
Publisher: Elsevier Science BV
Issue Date: 2013
ISSN: 0304-419X
1879-2561
Statement of
Responsibility: 
Margaret M. Centenera, Alyssa K. Fitzpatrick, Wayne D. Tilley, Lisa M. Butler
Abstract: Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the maturation, activation and stability of critical signaling proteins that drive the development and progression of prostate cancer, including the androgen receptor. Despite robust preclinical data demonstrating anti-tumor activity of first-generation Hsp90 inhibitors in prostate cancer, poor clinical responses initially cast doubt over the clinical utility of this class of agent. Recent advances in compound design and development, use of novel preclinical models and further biological insights into Hsp90 structure and function have now stimulated a resurgence in enthusiasm for these drugs as a therapeutic option. This review highlights how the development of new-generation Hsp90 inhibitors with improved physical and pharmacological properties is unfolding, and discusses the potential contexts for their use either as single agents or in combination, for men with metastatic prostate cancer.
Keywords: Hsp90; Inhibitors; Prostate cancer; Clinical trials
Rights: Copyright © 2013 Elsevier B.V. All rights reserved.
RMID: 0020124700
DOI: 10.1016/j.bbcan.2012.12.005
Grant ID: http://purl.org/au-research/grants/nhmrc/627185
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.